Details of the Drug

General Information of Drug (ID: DMTNFCQ)

• Drug Name: Levobunolol
• Synonyms: Akbeta; Betagan; Levobunololum; Levobunolol HCl; Betegan (TN); Levobunolol (INN); Levobunolol [INN:BAN]; Levobunololum [INN-Latin]; Liquifilm (TN); W-6412A; W-7000A; AK-Beta (TN); (-)-Bunolol; (S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2H)-one

Indication

Disease Entry	ICD 11	Status	REF
Open-angle glaucoma	9C61	Approved	[1], [2]

• Therapeutic Class: Sympatholytics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 291.4
  Topological Polar Surface Area (xlogp); 2.4
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption: The absorption of drug is 80% [3]
  Bioavailability: 75% of drug becomes completely available to its intended biological destination(s) [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 20 hours [5]
  Metabolism: The drug is metabolized via the hepatic [3]
• Chemical Identifiers:
  Formula: C17H25NO3
  IUPAC Name: 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one
  Canonical SMILES: CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O
  InChI: InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1
  InChIKey: IXHBTMCLRNMKHZ-LBPRGKRZSA-N
• Cross-matching ID:
  PubChem CID: 39468
  ChEBI ID: CHEBI:6438
  CAS Number: 47141-42-4
  DrugBank ID: DB01210
  TTD ID: D00IUG
  INTEDE ID: DR0933

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Antagonist	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[7]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Levobunolol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Bepridil	DM0RKS4	Moderate	Increased risk of cardiac depression by the combination of Levobunolol and Bepridil.	Angina pectoris [BA40]	[26]
Dronedarone	DMA8FS5	Moderate	Increased risk of bradycardia by the combination of Levobunolol and Dronedarone.	Angina pectoris [BA40]	[27]
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Levobunolol and Atracurium.	Corneal disease [9A76-9A78]	[28]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Levobunolol and Mivacurium.	Corneal disease [9A76-9A78]	[28]
Pancuronium	DMB0VY8	Moderate	Additive cardiorespiratory depression effects by the combination of Levobunolol and Pancuronium.	Corneal disease [9A76-9A78]	[28]
Pasireotide	DMHM7JS	Moderate	Increased risk of atrioventricular block by the combination of Levobunolol and Pasireotide.	Cushing syndrome [5A70]	[29]
Levamlodipine	DM92S6N	Moderate	Increased risk of cardiac depression by the combination of Levobunolol and Levamlodipine.	Hypertension [BA00-BA04]	[26]
Clevidipine butyrate	DMW4M97	Moderate	Increased risk of cardiac depression by the combination of Levobunolol and Clevidipine butyrate.	Hypertension [BA00-BA04]	[26]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Levobunolol caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[30]
Siponimod	DM2R86O	Major	Increased risk of atrioventricular block by the combination of Levobunolol and Siponimod.	Multiple sclerosis [8A40]	[31]
Fingolimod	DM5JVAN	Moderate	Increased risk of bradycardia by the combination of Levobunolol and Fingolimod.	Multiple sclerosis [8A40]	[32]
Ozanimod	DMT6AM2	Moderate	Increased risk of bradycardia by the combination of Levobunolol and Ozanimod.	Multiple sclerosis [8A40]	[33]
Polythiazide	DMCH80F	Moderate	Increased risk of hyperglycemia by the combination of Levobunolol and Polythiazide.	Oedema [MG29]	[34]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Levobunolol and Silodosin.	Prostate hyperplasia [GA90]	[35]
Pipecuronium	DM5F84A	Moderate	Additive neuromuscular blocking effects by the combination of Levobunolol and Pipecuronium.	Tonus and reflex abnormality [MB47]	[28]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Levobunolol and Vecuronium.	Tonus and reflex abnormality [MB47]	[28]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 570).
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [4] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] Binding of beta-adrenoceptor antagonists to rat and rabbit lung: special reference to levobunolol. Arzneimittelforschung. 1984;34(5):579-84.
• [7] Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
• [8] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [9] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [10] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [11] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [12] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [13] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [14] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [15] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [16] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [17] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [18] Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
• [19] Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
• [20] Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
• [21] Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
• [22] Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
• [23] Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
• [24] beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
• [25] beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
• [26] Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
• [27] Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
• [28] Harrah MD, Way WL, Katzung BG "The interaction of d-tubocurarine with antiarrhythmic drugs." Anesthesiology 33 (1970): 406-10. [PMID: 5512329]
• [29] Canadian Pharmacists Association.
• [30] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [31] Cerner Multum, Inc. "Australian Product Information.".
• [32] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [33] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [34] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
• [35] Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]